| Characteristics | All (N = 44) | Cyclin D1 | |
|---|
| | | Negative (N = 24) | Focal weak +ve (N = 5) | Diffuse strong +ve (N = 15) | p-value |
|---|
| | No. (%) | No. (%) | No. (%) | No. (%) | |
|---|
| Age (years) |
| Mean ± SD | 56.84 ±7.93 | 62.16 ±4.91 | 51.40 ±11.01 | 50.13 ±3.39 | <0.001* |
| Median (Range) | 57 (39-72) | 61.50 (56-72) | 50 (39-65) | 50 (44-55) | |
| ≤ 55 years | 18 (40.9%) | 0 (0%) | 3 (16.7%) | 15 (83.3%) | <0.001‡ |
| > 55 years | 26 (59.1%) | 24 (92.3%) | 2 (7.7%) | 0 (0%) | |
| Histopathology |
| LMS | 22 (50%) | 22 (100%) | 0 (0%) | 0 (0%) | <0.001‡ |
| ESS | 22 (50%) | 2 (9.1%) | 5 (22.7%) | 15 (68.2%) | |
| Grade |
| Grade I | 9 (20.5%) | 7 (77.8%) | 2 (22.2%) | 0 (0%) | 0.006‡ |
| Grade II | 12 (27.3%) | 7 (58.3%) | 3 (25%) | 2 (16.7%) | |
| Grade III | 23 (52.3%) | 10 (43.5%) | 0 (0%) | 13 (56.5%) | |
| Extrauterine extension |
| Absent | 6 (13.6%) | 6 (100%) | 0 (0%) | 0 (0%) | <0.001‡ |
| Present | 9 (20.5%) | 5 (55.6%) | 4 (44.4%) | 0 (0%) | |
| N/A | 29 (65.9%) | 13 (44.8%) | 1 (3.4%) | 15 (51.7%) | |
| LVSI |
| Absent | 21 (47.7%) | 16 (76.2%) | 5 (23.8%) | 0 (0%) | <0.001‡ |
| Present | 23 (52.3%) | 8 (34.8%) | 0 (0%) | 15 (65.2%) | |
| Bladder/Rectum extension |
| Absent | 33 (75%) | 20 (60.6%) | 4 (12.1%) | 9 (27.3%) | 0.017‡ |
| Present | 10 (22.7%) | 4 (40%) | 0 (0%) | 6 (60%) | |
| N/A | 1 (2.3%) | 0 (0%) | 1 (100%) | 0 (0%) | |
| Adnexal invasion |
| Absent | 11 (25%) | 9 (81.8%) | 2 (18.2%) | 0 (0%) | 0.022‡ |
| Present | 33 (75%) | 15 (45.5%) | 3 (9.1%) | 15 (45.5%) | |
| Lymph node |
| Negative | 16 (36.4%) | 12 (75%) | 4 (25%) | 0 (0%) | 0.001‡ |
| Positive | 28 (63.6%) | 12 (42.9%) | 1 (3.6%) | 15 (53.6%) | |
| Distant metastasis |
| Absent | 29 (65.9%) | 20 (69%) | 5 (17.2%) | 4 (13.8%) | <0.001‡ |
| Present | 15 (34.1%) | 4 (26.7%) | 0 (0%) | 11 (73.3%) | |
| FIGO Stage |
| Stage I | 6 (13.6%) | 6 (100%) | 0 (0%) | 0 (0%) | <0.001‡ |
| Stage II | 10 (22.7%) | 6 (60%) | 4 (40%) | 0 (0%) | |
| Stage III | 13 (29.5%) | 8 (61.5%) | 1 (7.7%) | 4 (30.8%) | |
| Stage IV | 15 (34.1%) | 4 (26.7%) | 0 (0%) | 11 (73.3%) | |
| Stathmin |
| Negative | 19 (43.2%) | 2 (10.5%) | 5 (26.3%) | 12 (63.2%) | <0.001‡ |
| Focal weak +ve | 12 (27.3%) | 10 (83.3%) | 0 (0%) | 2 (16.7%) | |
| Diffuse strong +ve | 13 (29.5%) | 12 (92.3%) | 0 (0%) | 1 (7.7%) | |
| Transgelin |
| Negative | 25 (56.8%) | 5 (20%) | 5 (20%) | 15 (60%) | <0.001‡ |
| Focal weak +ve | 6 (13.6%) | 6 (100%) | 0 (0%) | 0 (0%) | |
| Diffuse strong +ve | 13 (29.5%) | 13 (100%) | 0 (0%) | 0 (0%) | |
| BCOR |
| Negative | 23 (52.3%) | 21 (91.3%) | 2 (8.7%) | 0 (0%) | <0.001‡ |
| Focal weak +ve | 7 (15.9%) | 2 (28.6%) | 3 (42.9%) | 2 (28.6%) | |
| Diffuse strong +ve | 14 (31.8%) | 1 (7.1%) | 0 (0%) | 13 (92.9%) | |
- * Kruskal Wallis H test; ‡ Chi-square test; p < 0.05 is significant
